Targeting mitochondrial Kv1.3 enables precise autoreactive T cell therapy for multiple sclerosis

Multiple sclerosis (MS), a chronic autoimmune disorder, is characterized by the infiltration of autoreactive T cells into the central nervous system (CNS), leading to myelin destruction and neurological deficits. Current therapies often lack specificity, resulting in broad immunosuppression and potential side effects. In this issue of EMBO Molecular Medicine, Angi, Varanita and colleagues (Angi et al, 2025) identify a novel therapeutic strategy in targeting the mitochondrial Kv1.3 channel in autoreactive T cells, offering a more selective approach to mitigate MS-like pathology.